COMMUNIQUÉS West-GlobeNewswire

Parkinson’s Disease Pathogenesis may have a Bacterial Virus Component According to Research Conducted by Human Microbiology Institute

17/07/2018 - 13:32

Full study data published in Scientific Reports NEW YORK, July 17, 2018 (GLOBE NEWSWIRE) -- Human Microbiology Institute (HMI), a not-for-profit scientific research organization, and Tetz Laboratories today announced [...]

Innovation Pharmaceuticals Signs Drug Product Manufacturing Contract with CoreRx to Formulate and Package Brilacidin for Oral Mucositis in Sachet Form

17/07/2018 - 13:30

BEVERLY, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the Company has signed a Drug Product [...]

Eloxx Pharmaceuticals To Report Second Quarter 2018 Financial Results On August 7, 2018 and Host Webcast and Conference Call

17/07/2018 - 13:30

WALTHAM, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic [...]

VitalHub Announces First Municipal Client Sale for VH LTC Solution

17/07/2018 - 13:30

TORONTO, July 17, 2018 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSXV:VHI) is pleased to announce the sale of VH LTC solution to the Seniors’ Services division of the Region of Waterloo, marking [...]

The Lefebvre Foundation: Man taking seven million steps for cancer will walk from North Bay to Quebec in coming weeks

17/07/2018 - 13:18

NORTH BAY, Ontario, July 17, 2018 (GLOBE NEWSWIRE) -- When Jimmy Lefebvre lost his father to cancer he couldn’t accept how his father was forced to quickly succumb to the disease. Lefebvre is now over half-way across [...]

Voyager Therapeutics Receives FDA Guidance on Development Path for VY-AADC for Parkinson’s Disease and Provides Clinical Update

17/07/2018 - 13:04

Voyager continues to plan to submit a BLA for VY-AADC based on its pivotal program and Type C meeting feedback Positive interim results with VY-AADC from the Phase 1 posterior trajectory trial supports the surgical [...]

Asterias Provides Six Month Data Readout for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury

17/07/2018 - 13:00

- Current Readout Includes New Six Month Data for Cohort 5 and Aggregate Trial Data - - Results Continue to Demonstrate Favorable Safety Profile, Potential for Durable Cell Engraftment at the Injury Site and Improved [...]

Evogene and IMAmt Enter a Collaboration in the Field of Insect Resistance Traits in Cotton

17/07/2018 - 13:00

Evogene will identify candidate toxins mainly against Cotton Boll Weevil and IMAmt will validate the toxins REHOVOT, Israel and CUIABÁ/MT, Brazil, July 17, 2018 (GLOBE NEWSWIRE) -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN [...]

Resverlogix Announces Upcoming Presentations at Clinical Trials in Alzheimer’s Disease (CTAD) Asia and Alzheimer’s Association International Conference (AAIC)

17/07/2018 - 13:00

CALGARY, Alberta, July 17, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today that it has been awarded two presentations at the Clinical Trials in Alzheimer’s Disease ( [...]

BioTelemetry, Inc. to Release Second Quarter 2018 Earnings Results on July 25, 2018

17/07/2018 - 13:00

MALVERN, Pa., July 17, 2018 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its second quarter 2018 earnings on Wednesday, July 25 at 4:00 PM Eastern Time. The BioTelemetry quarterly conference call [...]

Axsome Therapeutics Announces AXS-05 Presentation at the 2018 Alzheimer’s Association International Conference

17/07/2018 - 13:00

NEW YORK, July 17, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, [...]

Capricor and USAISR Announce Collaboration to Investigate Exosome Platform to Treat Injured Troops

17/07/2018 - 13:00

Research to Explore Potential for CAP-2003 to Address Trauma-related Injuries LOS ANGELES, July 17, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced it has entered into an agreement with the [...]

Auxly Congratulates Streaming Partner CannTx Life Sciences on Obtaining Cultivation Licence

17/07/2018 - 13:00

VANCOUVER, British Columbia, July 17, 2018 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX.V:XLY) (" Auxly " or the " Company ") is pleased to announce that Auxly’s streaming partner, CannTx Life Sciences Inc. (“ [...]

APEIRON Appoints Peter Llewellyn-Davies as Chief Executive Officer

17/07/2018 - 12:00

The Former CEO, Dr. Hans Loibner, Will Continue to Support the Company as Senior Advisor VIENNA, Austria, July 17, 2018 (GLOBE NEWSWIRE) -- APEIRON Biologics AG, a company focused on cancer immunotherapy, today [...]

PotNetwork Holdings, Inc., With Sales of Over $10 Million Year-To-Date, Moves Toward Uplisting and Expansion

17/07/2018 - 12:00

FT. LAUDERDALE, Fla., July 17, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE--PotNetwork Holdings, Inc. (OTC Pink:POTN) on July 13 th , the Company announced that it had filed a Form 10 registration statement with the [...]

Transactions in relation to share buyback program

17/07/2018 - 10:49

Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]

Crenezumab's Second Phase 3 Trial (CREAD 2) Fully Recruited - Updates on AC Immune's Pipeline and Technology Platforms to be presented at AAIC in Chicago

17/07/2018 - 10:01

Crenezumab's Second Phase 3 Trial (CREAD 2) Fully Recruited - Updates on AC Immune's Pipeline and Technology Platforms to be presented at the Alzheimer's Association International Conference in Chicago Lausanne, [...]

Enzymatica AB: Lower sales in Q2 but 31% increase for the first half of the year

17/07/2018 - 08:31

Interim report for Enzymatica AB (publ) JANUARY-JUNE 2018 Lower sales in Q2 but 31% increase for the first half of the year Q2 Net sales reached SEK 5.3 (5.9) million. Net profit after tax came in at SEK -15.5 (-10.8) [...]

CellaVision AB: Interim Report January-June 2018

17/07/2018 - 08:21

Good sales growth in all regions April 1-June 30, 2018 Net sales increased by 17% to SEK 91.9 million (78.7). Organic growth was 15%. Operating profit was SEK 31.6 million (24.6). Operating margin was 34.4% (31.3). [...]